Multiple sclerosis and cognitive decline: Is ApoE-4 a surrogate marker?

Acta Neurologica Scandinavica

Volumn 124, Issue 4, 2011, Pages 258-263

  Carmona, O ^a   Masuet, C ^a   Santiago, O ^a   Alia P ^a   Moral, E ^a   Alonso Magdalena, L ^a   Casado, V ^a   Arbizu, T ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Apolipoprotein E 4; Clinical markers; Cognitive decline; Interferon beta; Multiple sclerosis

Indexed keywords

APOLIPOPROTEIN E4; BETA INTERFERON;

ADULT; ARTICLE; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; CORRELATION ANALYSIS; DISABILITY; FEMALE; GENOTYPE; HUMAN; MALE; MULTIPLE SCLEROSIS; NEUROPSYCHOLOGICAL TEST;

ADULT; AGED; APOLIPOPROTEIN E4; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; COGNITION DISORDERS; DISABILITY EVALUATION; FEMALE; GENOTYPE; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NEUROPSYCHOLOGICAL TESTS; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 80053079821     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2010.01473.x     Document Type: Article

References (48)

1. Peyser JM, Rao SM, La Rocca NG, Kaplan E. Guidelines for neuropsychological research in multiple sclerosis. Arch Neurol 1990;47:94-7.
2. Jasen DA, Cimprich B. Attentional impairment in persons with multiple sclerosis. J Neurosci Nurs 1994;26:95-102.
3. Grassiot B, Desgranges B, Eustache F, Defer G. Quantification and clinical relevance of brain atrophy in multiple sclerosis: a review. J Neurol 2009;256:1397-412.
4. Summers M, Swanton J, Fernando K et al. Cognitive impairment in multiple sclerosis can be predicted by imaging early in the disease. J Neurol Neurosurg Psychiatry 2008;79:955-8.
5. Shulz D, Kopp B, Kunkel A, Faiss JH. Cognition in the early stage of multiple sclerosis. J Neurol 2006;253:1002-10.
6. Minden SL, Orav J, Reich P. Depression in multiple sclerosis. Gen Hosp Psychiatry 1987;9:426-34.
7. Sanz J, Vazquez C. Fiabilidad, validez y datos normativos del inventario de depresión de Beck. Psicothema 1998;10:303-18.
8. Saunders AM, Strittmatter WJ, Schmechel D et al. Association of apolipoprotein E allele epsillon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993;43:1467-72.
9. Dik MG, Jonker C, Comijs HC et al. Memory complaints and APOE-epsillon 4 accelerate cognitive decline in cognitively normal elderly. Neurology 2001;57:2217-22.
10. Oliveri RL, Cittadella R, Sibilia G et al. APOE and risk of cognitive impairment in multiple sclerosis. Acta Neurol Scand 1999;100:290-5.
11. Savettieri G, Messina D, Andreoli V et al. Gender-related effect of clinical and genetic variables on the cognitive impairment in multiple sclerosis. J Neurol 2004;251:1208-14.
12. Shi J, Zhao CB, Vollmer TL, Tyry TM, Kuniyoshi SM. APOE epsilon 4 allele is associated with cognitive impairment in patients with multiple sclerosis. Neurology 2008;70:185-90.
13. Szolnoki Z, Kondacs A, Mandi Y, Somogyyari F. Characteristic imprint of single nucleotide polymorphisms in multiple sclerosis. J Mol Neurosci 2009;38:166-72.
14. Szolnoki Z, Kondacs A, Mandi Y, Bodor A, Somogyyari F. A homozygous genetic variant of mitochondrial uncoupling protein 4 exerts protection against the occurrence of multiple sclerosis. Neuromolecular Med 2009;11:101-5.
15. La Russa A, Cittadella R, De Marco EV et al. Single nucleotide polymorphism in the MMP-9 gene is associated with susceptibility to develop multiple sclerosis in an Italian case-control study. J Neuroimmunol 2010;2:175-9.
16. Hoffjan S, Akkad DA. The genetics of multiple sclerosis: an update 2010. Mol Cell Probes 2010;24:237-43.
17. Okuda DT, Srinivasan R, Oksenberg JR et al. Genotype-Phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by HMR spectroscopy and MRI measures. Brain 2009;132:250-9.
18. Mc Donald WI, Compston A, Edan G et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-7.
19. Polman CH, Reingold SC, Edan G et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005;58:840-6.
20. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52.
21. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990;31:545-8.
22. Peña J, Guardia J, Bertran I, Manero RM, Jarne A. Versión abreviada del Test Barcelona. Neurologia 1997;12:99-110.
23. Smith A. The symbol-digit modalities test: a neuropsychologic test of learning and other cerebral disorders. In: Helmuth J, ed. Learning disorders. Seattle: Special Child Publications, 1968;83-91.
24. Achiron A, Polliack M, Rao SM et al. Cognitive patterns and progression in multiple sclerosis: construction and validation of percentile curves. J Neurol Neurosurg Psychiatry 2005;76:744-9.
25. Golden J. Stroop. Test de Colores y palabras. In: TEA eds. Madrid, 1995.
26. Heaton RK, Chelune GJ, Talley JL, Kay GG, Curtiss G. Test de Clasificación de tarjetas de Wisconsin. In: TEA eds. Madrid, 1997.
27. Wechsler DS. Wechsler Adult Intelligence Scale. In: Psychological Corporation, eds. Manual. New York, 1995.
28. Conde V, Useros E. Cuestionario de Beck. Adaptación española. Rev Psiquiatr Psicol Med Eur Am Lat 1975;12:217-36.
29. Amato MP, Ponziani G, Pracucci G, Bracco L, Siracusa G, Amaducci L. Cognitive impairment in early onset multiple sclerosis. Pattern, predictors, and impact on everyday life in a 4-year follow-up. Arch Neurol 1995;52:168-72.
30. Amato MP, Ponziani G, Siracusa G, Sorbi S. Cognitive dysfunction in early-onset multiple sclerosis: a reappraisal after 10years. Arch Neurol 2001;58:1602-6.
31. Huijbregts SC, Kalkers NF, De Sonneville LM, De Groot V, Polman CH. Cognitive impairment and decline in different MS subtypes. J Neurol Sci 2006;2:187-94.
32. Glanz B, Holland C, Gauthier S et al. Cognitive disfunction in patients with clinically isolated syndromes or newly diagnosed multiple sclerosis. Mult Scler 2007;13:1004-10.
33. Feuillet L, Reuter F, Audoin B et al. Early cognitive impairment in patients with clinically isolated syndrome suggestive of multiple sclerosis. Mult Scler 2007;13:124-7.
34. Zipoli V, Goretti B, Hakiki B et al. Cognitive impairment predicts conversion to multiple sclerosis in clinically isolated syndromes. Mult Scler 2010;16:62-7.
35. Zivadinov R, Sepcic J, Nasuelli D et al. A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 2001;70:773-80.
36. Koutsis G, Chir B, Panas M et al. APOE epsillon4 is associated with impaired verbal learning in patients with MS. Neurology 2007;68:546-9.
37. Rubinsztein DC, Hanlon CS, Irving RM et al. ApoE genotypes in multiple sclerosis, Parkinson's disease, schwanomas and late-onset Alzheimer's disease. Mol Cell Probes 1994;8:519-25.
38. Gervais A, Gaillard O, Plassart E, Reboul J, Fontaine B, Schuller E. Apolipoprotein E polymorphism in multiple sclerosis. Ann Clin Biochem 1998;35:135-6.
39. Lanzillo R, Prinster A, Scarano V et al. Neuropsychological assessment, quantitative MRI and APOE gene polymorphisms in a series of MS patients treated with IFN beta-1b. J Neurol Sci 2006;2:141-5.
40. Ghaffar O, Reis M, Pennell N, O'connor P, Feinsten A. APOE4 and the cognitive genetics of multiple sclerosis. Neurology 2010;74:1611-8.
41. Beatty WW, Goodkin DE, Herstgaard D, Monson N. Clinical and demographic predictors of cognitive performance in multiple sclerosis: do diagnostic type, disease duration and disability matter? Arch Neurol 1990;47:305-8.
42. Herlitz A, Yonyer JE. Sex differences in episodic memory: the influence of intelligence. J Clin Exp Neuropsychol 2002;24:107-14.
43. Parmenter BA, Denney DR, Lynch SG, Middleton LS, Harlan LM. Cognitive impairment in patients with multiple sclerosis: association with the APOE gene and promoter polymorphisms. Mult Scler 2007;13:25-32.
44. De Stefano N, Bartolozzi ML, Nacmias B et al. Influence of apoliproprotein E epsilon4 genotype on brain tissue integrity in relapsing-remitting multiple sclerosis. Arch Neurol 2004;61:536-40.
45. Portaccio E, Goretti B, Zipoli V et al. APOE-e4 is not associated with cognitive impairment in relapsing-remitting multiple sclerosis. Mult Scler 2009;15:1489-94.
46. Patti F, Amato MP, Trojano M et al. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study. Mult Scler 2009;15:779-88.
47. Fletcher S, Vardi J, Finkelstein Y, Pollak L. Cognitive dysfunction evaluation in multiple sclerosis patients treated with interferon beta-1b: an open-label prospective 1year study. Isr Med Assoc J 2007;9:457-9.
48. Kappos L, Freedman MS, Polman CH et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: a 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 2009;8:987-97.